Childrens Hospital
- Type
- Teaching hospital
- Where
- Washington, DC
- Medicare CCN
- 093300
- Received
- $1,537,805 in 96 records, 2025 ($783,952 general, $753,852 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 30 | $783,952 |
| 2025 | Research payment | 66 | $753,852 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 17 | $736,011 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $654,000 | 2025 |
| MED-EL Corporation | 1 | $66,140 | 2025 |
| Berlin Heart Inc | 2 | $15,270 | 2025 |
| QIAGEN, LLC | 1 | $10,000 | 2025 |
| National Marrow Donor Program | 5 | $8,915 | 2025 |
| Siemens Medical Solutions USA, Inc. | 2 | $5,191 | 2025 |
| Merck Sharp & Dohme LLC | 2 | $5,000 | 2025 |
| PFIZER INC. | 2 | $5,000 | 2025 |
| Neurelis, Inc. | 2 | $4,200 | 2025 |
| Baxter Healthcare | 2 | $4,128 | 2025 |
| Regeneron Healthcare Solutions, Inc. | 1 | $4,000 | 2025 |
| Haemonetics Corporation | 1 | $3,686 | 2025 |
| Abbott Laboratories | 1 | $3,500 | 2025 |
| Mallinckrodt Hospital Products Inc. | 1 | $3,500 | 2025 |
| AstraZeneca Pharmaceuticals LP | 1 | $2,500 | 2025 |
| SANOFI-AVENTIS U.S. LLC | 1 | $2,500 | 2025 |
| Bio-Rad Laboratories, Inc. | 2 | $1,016 | 2025 |
| OrthoPediatrics Corp. | 1 | $1,000 | 2025 |
| JAZZ PHARMACEUTICALS INC. | 41 | $957 | 2025 |
| Linvatec Corporation | 1 | $506 | 2025 |
| Dexcom, Inc. | 1 | $369 | 2025 |
| Incyte Corporation | 4 | $244 | 2025 |
| Olympus America Inc. | 2 | $168 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 66 | $753,852 |
| Grant | 4 | $661,200 |
| Long term medical supply or device loan | 2 | $66,646 |
| Space rental or facility fees (teaching hospital only) | 9 | $35,000 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 7 | $13,869 |
| Debt forgiveness | 6 | $4,236 |
| Education | 1 | $2,000 |
| Consulting Fee | 1 | $1,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $191 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-12-09 | Mallinckrodt Hospital Products Inc. | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | 2025 | |
| 2025-12-09 | Novartis Pharmaceuticals Corporation | $2,348 | Research payment | Cash or cash equivalent | A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic | 2025 | |
| 2025-12-08 | JAZZ PHARMACEUTICALS INC. | $21 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-12-08 | JAZZ PHARMACEUTICALS INC. | $11 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-12-08 | JAZZ PHARMACEUTICALS INC. | $3 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-12-04 | Merck Sharp & Dohme LLC | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ROTATEQ Biological, VACCINE | 2025 | |
| 2025-11-19 | Novartis Pharmaceuticals Corporation | $326,960 | Research payment | In-kind items and services | PIQRAY Drug, Oncology | EPIK-L1: a phase II/III double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacoki | 2025 |
| 2025-11-18 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FLUMIST QUADRIVALENT Biological, Respiratory | 2025 | |
| 2025-11-17 | PFIZER INC. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-15 | Novartis Pharmaceuticals Corporation | $8,937 | Research payment | In-kind items and services | KYMRIAH Drug, Oncology | A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic | 2025 |
| 2025-11-05 | Bio-Rad Laboratories, Inc. | $62 | Debt forgiveness | Cash or cash equivalent | IH Systems Device, Not Applicable | 2025 | |
| 2025-10-28 | Berlin Heart Inc | $7,650 | Research payment | Cash or cash equivalent | Device | EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study | 2025 |
| 2025-10-24 | National Marrow Donor Program | $1,000 | Research payment | Cash or cash equivalent | A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research | 2025 | |
| 2025-10-17 | National Marrow Donor Program | $890 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-15 | Baxter Healthcare | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TISSEEL Biological, Surgical Care | 2025 | |
| 2025-10-14 | QIAGEN, LLC | $10,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-09-30 | Olympus America Inc. | $20 | Debt forgiveness | In-kind items and services | COMMUNICATION CABLE 1.8M Device, Gastroenterology | 2025 | |
| 2025-09-25 | Novartis Pharmaceuticals Corporation | $18,375 | Research payment | Cash or cash equivalent | A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with | 2025 | |
| 2025-09-19 | Siemens Medical Solutions USA, Inc. | $5,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-09-15 | Novartis Pharmaceuticals Corporation | $91 | Research payment | In-kind items and services | KYMRIAH Drug, Oncology | A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic | 2025 |
| 2025-09-10 | Haemonetics Corporation | $3,686 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-09-04 | Novartis Pharmaceuticals Corporation | $2,980 | Research payment | Cash or cash equivalent | TAFINLAR Drug, Oncology | An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabr | 2025 |
| 2025-08-21 | Novartis Pharmaceuticals Corporation | $37,591 | Research payment | Cash or cash equivalent | ADAKVEO Drug, Hematology | An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N | 2025 |
| 2025-08-08 | Incyte Corporation | $91 | Research payment | Cash or cash equivalent | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2025 | |
| 2025-08-08 | Incyte Corporation | $64 | Research payment | Cash or cash equivalent | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2025 | |
| 2025-08-08 | Incyte Corporation | $59 | Research payment | Cash or cash equivalent | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2025 | |
| 2025-08-08 | Incyte Corporation | $29 | Research payment | Cash or cash equivalent | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2025 | |
| 2025-07-23 | National Marrow Donor Program | $3,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-09 | JAZZ PHARMACEUTICALS INC. | $42 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-07-09 | JAZZ PHARMACEUTICALS INC. | $35 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-07-09 | JAZZ PHARMACEUTICALS INC. | $35 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-07-09 | JAZZ PHARMACEUTICALS INC. | $11 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-07-09 | JAZZ PHARMACEUTICALS INC. | $11 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-07-09 | JAZZ PHARMACEUTICALS INC. | $11 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-07-09 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-07-09 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-07-09 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-07-09 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-06-30 | Olympus America Inc. | $147 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-06-24 | Novartis Pharmaceuticals Corporation | $9,275 | Research payment | Cash or cash equivalent | ZOLGENSMA Drug, Neurology | Retrospective Chart Review of Zolgensma (onasemnogene abeparvovec) Intravenous (IV) in Spinal Muscular Atrophy (SMA) pat | 2025 |
| 2025-06-16 | Regeneron Healthcare Solutions, Inc. | $4,000 | Grant | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-02 | Novartis Pharmaceuticals Corporation | $12,009 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multice | 2025 |
| 2025-06-02 | Novartis Pharmaceuticals Corporation | $11,916 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multice | 2025 |
| 2025-05-29 | Merck Sharp & Dohme LLC | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PROQUAD Biological, VACCINE | 2025 | |
| 2025-05-29 | SANOFI-AVENTIS U.S. LLC | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TZIELD Biological, Endocrine & Metabolic Diseases | 2025 | |
| 2025-05-16 | PFIZER INC. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TRUMENBA Biological, VACCINES | 2025 | |
| 2025-04-25 | Neurelis, Inc. | $2,000 | Education | Cash or cash equivalent | VALTOCO Drug, EPILEPSY | 2025 | |
| 2025-04-25 | National Marrow Donor Program | $1,115 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-10 | Linvatec Corporation | $506 | Long term medical supply or device loan | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2025 | |
| 2025-04-08 | JAZZ PHARMACEUTICALS INC. | $27 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-04-08 | JAZZ PHARMACEUTICALS INC. | $9 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-04-08 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-04-08 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-04-08 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-04-08 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-04-04 | Takeda Pharmaceuticals U.S.A., Inc. | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-03-28 | Baxter Healthcare | $128 | Debt forgiveness | In-kind items and services | Device, Trauma (Emergency, Injury, Surgery) | 2025 | |
| 2025-03-20 | MED-EL Corporation | $66,140 | Long term medical supply or device loan (8 payments) | In-kind items and services | Mi1250 SYNCHRONY 2 FLEXsoft Device, Cochlear Implant | 2025 | |
| 2025-03-19 | Bio-Rad Laboratories, Inc. | $954 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | Antibody Device, Market Research | 2025 | |
| 2025-03-17 | Neurelis, Inc. | $2,200 | Grant | Cash or cash equivalent | VALTOCO Drug, EPILEPSY | 2025 | |
| 2025-03-12 | Novartis Pharmaceuticals Corporation | $70,806 | Research payment | In-kind items and services | XOLAIR Drug, Pulmonary/Respiratory Diseases | Omalizumab Before Onset of Exacerbations URI-induc. asthma exacerbation | 2025 |
| 2025-03-10 | Dexcom, Inc. | $369 | Research payment | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | CAMP: CGM-Assisted Management of PN | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $127 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $106 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $68 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $54 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $42 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $42 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $42 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $42 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $20 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $11 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $11 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $4 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $4 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-10 | JAZZ PHARMACEUTICALS INC. | $4 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-03-06 | Novartis Pharmaceuticals Corporation | $45,318 | Research payment | Cash or cash equivalent | TAFINLAR Drug, Oncology | An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabr | 2025 |
| 2025-03-06 | Novartis Pharmaceuticals Corporation | $12,027 | Research payment | Cash or cash equivalent | MAYZENT Drug, Neurology | A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Sipo | 2025 |
| 2025-03-05 | OrthoPediatrics Corp. | $1,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-01 | Novartis Pharmaceuticals Corporation | $9,882 | Research payment | Cash or cash equivalent | ADAKVEO Drug, Hematology | A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizu | 2025 |
| 2025-02-24 | Abbott Laboratories | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Structural Heart | 2025 | |
| 2025-02-10 | Berlin Heart Inc | $7,620 | Research payment | Cash or cash equivalent | Device | EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study | 2025 |
| 2025-02-10 | JAZZ PHARMACEUTICALS INC. | $23 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-02-10 | JAZZ PHARMACEUTICALS INC. | $11 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-02-10 | JAZZ PHARMACEUTICALS INC. | $11 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-02-10 | JAZZ PHARMACEUTICALS INC. | $11 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-02-10 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-02-10 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-02-10 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-02-10 | JAZZ PHARMACEUTICALS INC. | $7 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2 | 2025 |
| 2025-01-30 | Novartis Pharmaceuticals Corporation | $36,035 | Research payment | Cash or cash equivalent | A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) | 2025 | |
| 2025-01-24 | National Marrow Donor Program | $2,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-01-20 | Takeda Pharmaceuticals U.S.A., Inc. | $650,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-01-17 | Novartis Pharmaceuticals Corporation | $3,750 | Research payment | Cash or cash equivalent | ADAKVEO Drug, Hematology | A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with | 2025 |
| 2025-01-14 | Novartis Pharmaceuticals Corporation | $127,704 | Research payment | Cash or cash equivalent | ADAKVEO Drug, Hematology | An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Washington, DC, county District of Columbia, DC, state District of Columbia; placed by its city name.
| Measure | Place (city or town) Washington, DC | County District of Columbia, DC | State District of Columbia |
|---|---|---|---|
| Population B01003 | 681,294 | 681,294 | 681,294 |
| Population, 2020 census P1 | 689,545 | 689,545 | 689,545 |
| Median age B01002 | 34.9 | 34.9 | 34.9 |
| Under 18 B01001 | 18.7% | 18.7% | 18.7% |
| 65 and over B01001 | 12.8% | 12.8% | 12.8% |
| Households B11001 | 324,491 | 324,491 | 324,491 |
| Foreign born B05002 | 14.3% | 14.3% | 14.3% |
| Median household income B19013 | $109,870 | $109,870 | $109,870 |
| Median family income B19113 | $155,025 | $155,025 | $155,025 |
| Per capita income B19301 | $77,348 | $77,348 | $77,348 |
| Poverty rate B17001 | 15.4% | 15.4% | 15.4% |
| Unemployment rate B23025 | 6.3% | 6.3% | 6.3% |
| Civilian labor force B23025 | 400,406 | 400,406 | 400,406 |
| Mean commute (minutes) B08013 | 30.0 | 30.0 | 30.0 |
| Bachelor's degree or higher B15003 | 64.2% | 64.2% | 64.2% |
| Housing units B25001 | 361,014 | 361,014 | 361,014 |
| Owner-occupied B25003 | 41.5% | 41.5% | 41.5% |
| Renters B25003 | 58.5% | 58.5% | 58.5% |
| Median home value B25077 | $737,100 | $737,100 | $737,100 |
| Median gross rent B25064 | $1,954 | $1,954 | $1,954 |
| White, not Hispanic B03002 | 36.5% | 36.5% | 36.5% |
| Black B03002 | 41.6% | 41.6% | 41.6% |
| Hispanic or Latino B03002 | 11.9% | 11.9% | 11.9% |
| Asian B03002 | 4.3% | 4.3% | 4.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 5.6% in Sep 2026 (6.6% a year earlier); per capita personal income $119,772 in 2025, up 32% in five years (+6.5% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Washington, DC.
Comments